The authors concluded that leronlimab, combined with carboplatin, was well tolerated at each dose level and that leronlimab showed early evidence of anti-tumor activity in CCR5+ metastatic triple-negative breast cancer patients [111]. Here, CCR5 is linked to triple-negative breast carcinoma.